Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment
Yıl: 2020 Cilt: 35 Sayı: 2 Sayfa Aralığı: 300 - 302 Metin Dili: İngilizce DOI: 10.46497/ArchRheumatol.2020.7555 İndeks Tarihi: 13-10-2020
Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
- 1. Uchida S, Oiso N, Komeda Y, Kudo M, Kawada A. Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis. Eur J Dermatol 2018 Nov 13.
- 2. Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab. J Crohns Colitis 2018 May 9.
- 3. Wang J, Bhatia A, Krugliak Cleveland N, Gupta N, Dalal S, Rubin DT, et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Rep J 2018;5:e56.
- 4. Ehrlich D, Jamaluddin N, Pisegna J, Padua D. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Rep Gastrointest Med 2018;2018:9679287.
- 5. Shiga H, Fukuda S, Iijima K. Interleukin-17A inhibitorinduced Crohn’s Disease/Behçet’s disease-like lesions. Inflamm Bowel Dis 2017;23:38-9.
- 6. Vernero M, Astegiano M, Ribaldone DG. New onset of inflammatory bowel disease in three patients undergoing il-17a inhibitor secukinumab: a case series. Am J Gastroenterol 2019;114:179-80.
- 7. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700.
- 8. Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019;78:473-9.
- 9. Deodhar AA, Gladman DD, McInnes IB, van Den Bosch F, Shete A, You R, et al. Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure. Arthritis Rheumatol. 2018;70(Suppl 10). [Abstract] Available from: https://acrabstracts. org/abstract/post-marketing-safety-of-secukinumabin- adult-patients-with-psoriasis-psoriatic-arthritis-andankylosing- spondylitis-cumulative-analysis-across-9- 6000-patient-treatment-years-exposure/
- 10. Kumar P, Monin L, Castillo P, Elsegeiny W, Horne W, Eddens T, et al. Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity 2016;44:659-71.
- 11. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 2009;58:1152-67.
APA | Yazisiz V, uçar i, aslan b, Erbasan Çakır F, terzioglu e (2020). Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. , 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
Chicago | Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. (2020): 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
MLA | Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. , 2020, ss.300 - 302. 10.46497/ArchRheumatol.2020.7555 |
AMA | Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. . 2020; 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
Vancouver | Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. . 2020; 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
IEEE | Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment." , ss.300 - 302, 2020. 10.46497/ArchRheumatol.2020.7555 |
ISNAD | Yazisiz, Veli vd. "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment". (2020), 300-302. https://doi.org/10.46497/ArchRheumatol.2020.7555 |
APA | Yazisiz V, uçar i, aslan b, Erbasan Çakır F, terzioglu e (2020). Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology, 35(2), 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
Chicago | Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology 35, no.2 (2020): 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
MLA | Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology, vol.35, no.2, 2020, ss.300 - 302. 10.46497/ArchRheumatol.2020.7555 |
AMA | Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology. 2020; 35(2): 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
Vancouver | Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology. 2020; 35(2): 300 - 302. 10.46497/ArchRheumatol.2020.7555 |
IEEE | Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment." Archives of Rheumatology, 35, ss.300 - 302, 2020. 10.46497/ArchRheumatol.2020.7555 |
ISNAD | Yazisiz, Veli vd. "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment". Archives of Rheumatology 35/2 (2020), 300-302. https://doi.org/10.46497/ArchRheumatol.2020.7555 |